SCHEMBL4849527

SCHEMBL4849527

CC(c1ccnc(C(=O)O)c1)C1(C(C)c2ccnc(C(=O)O)c2)NC(=O)N(c2ccc(OC(F)(F)F)cc2)C1=O

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 9/20 0.37
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP3A4 P08684 1/20 0.36
GAA P10253 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
GPR139 Q6DWJ6 1/20 0.36
KDM5A P29375 1/20 0.36
KDM2B Q8NHM5 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
MARS1 P56192 1/20 0.35
AR P10275 1/20 0.35
ABL1 P00519 1/20 0.35
ALDH1A1 P00352 1/20 0.35
RAF1 P04049 1/20 0.34
EPHX2 P34913 1/20 0.34
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6173023 0.93 IGF1R (0.38) PDE2APOLBL3MBTL1CYP3A4GAA
SCHEMBL6171821 0.90 PDE2A (0.39) PDE2APOLBL3MBTL1CYP3A4GAA
SCHEMBL6174541 0.89 SLC5A1 (0.40) PDE2APOLBL3MBTL1CYP3A4GAA
SCHEMBL6174008 0.86 POLB (0.41) PDE2APOLBL3MBTL1CYP3A4GAA
SCHEMBL17558396 0.86 POLB (0.39) PDE2APOLBL3MBTL1CYP3A4GAA
SCHEMBL6178301 0.85 EPHX2 (0.41) GPR139ABL1EPHX2
SCHEMBL6173212 0.85 ADRB3 (0.40) PDE2APOLBL3MBTL1CYP3A4GAA
SCHEMBL6175359 0.85 POLB (0.38) PDE2APOLBL3MBTL1CYP3A4GAA
SCHEMBL6176573 0.85 KCNA5 (0.41) POLBCYP3A4GAACYP2C9CYP2C19
SCHEMBL6174941 0.85 IGF1R (0.45) PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed